Bausch & Lomb

Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024

Retrieved on:

Wednesday, March 13, 2024

“Nicox is focusing its resources on the Denali Phase 3 pivotal trial of its lead asset NCX 470 in glaucoma.

Key Points:

“Nicox is focusing its resources on the Denali Phase 3 pivotal trial of its lead asset NCX 470 in glaucoma.
We are reducing costs, including the size of the organization, and are exploring advancing NCX 1728, through collaborations.
In January 2024, Nicox expanded the territory of the exclusive licensing agreement with Harrow, Inc., to include Canada.
The Company is financed to at least November 2024, based on focusing exclusively on the development of NCX 470.

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on:

Wednesday, March 27, 2024

Science, Other Science, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Momentum, YAG, Toric, Failure, IOP, Retinal, Glaucoma, Exercise, DSM-IV codes, Neuropathic pain, ASCRS, History, Sale, Contact, Dry, Refraction, Bausch & Lomb, Eye, System, Keratoconus, Medication discontinuation, Pain, Corneal topography, Telecanthus, Astigmatism, Aphakia, Correction, Uveitis, Surgeon, Diabetes, Risk, Eye injury, CTK, Retinal detachment, Side, Trial of the century, Visual acuity, Diagnosis, Safety, Contraindication, Emmetropia, Vision, Taste, Dry eye syndrome, Intraocular lens, Presbyopia, Real, Floater, Magnetic resonance, Contrast (vision), Human, GLARE, Infection, Use, FDA, Ranibizumab, Muscular dystrophy, Sickle cell disease, Refractive surgery, Retina, Direction, IDE, Allergy, User, Society, Bleeding, Autoimmune disease

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points:

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
Bausch + Lomb activities at ASCRS:
“Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
“Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
“Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.

Senior Ophthalmology Executive Thomas A. (Tom) Dunlap Joins WaveFront Dynamics Inc. as an Independent Member of the Board of Directors to Support the Company’s Ongoing Commercialization and Broader Strategic Initiatives

Retrieved on:

Wednesday, March 20, 2024

Venture Capital, Medical Devices, Health, Professional Services, Optical, Wavefront, Coherence, WDI, Patient, Ophthalmic, University, Bausch & Lomb, MBA, Tom, Multimedia, Physician, Management

View the full release here: https://www.businesswire.com/news/home/20240320844399/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20240320844399/en/
Senior Ophthalmology Executive Thomas A.
(Tom) Dunlap joins WaveFront Dynamics Inc. as an Independent member of the Board of Directors to support the company’s ongoing commercialization and broader strategic initiatives.
(Photo: Business Wire)
“We are pleased to have Tom Dunlap join our Board of Directors.
He brings experience as an Independent Board member, Non-Executive Director, and Chairman of the Board with private Ophthalmic medical device companies.

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Appoints Renowned Oculoplastic Surgeon, John P. Fezza, MD to Its Medical Advisory Board

Retrieved on:

Thursday, March 14, 2024

Biotechnology, Surgery, Health, Pharmaceutical, Optical, MAB, Drainage, Alcon, Private practice, Telecanthus, Patient, Bausch & Lomb, MBA, Ophthalmology, Optometry, FDA, Pharma, Pharmaceutical industry

Dr. Fezza joins the MAB as Nordic Pharma prepares to launch a novel therapy for Dry Eye Disease, LACRIFILL® Canalicular Gel.

Key Points:

Dr. Fezza joins the MAB as Nordic Pharma prepares to launch a novel therapy for Dry Eye Disease, LACRIFILL® Canalicular Gel.
The FDA-cleared, cross-linked hyaluronic acid derivative LACRIFILL is intended to temporarily block tear drainage by the occlusion of the canalicular system.
“The entire U.S. Medical Advisory Board of Nordic Pharma is honored and delighted to welcome John Fezza, MD, a world class oculoplastic surgeon to our MAB,” said Eric Donnenfeld, MD, MAB Chair.
Nordic Pharma is committed to engaging ophthalmologists and optometrists in the early launch stages of LACRIFILL Canalicular Gel.

commercetools Accelerates Global Momentum, Announces Strong 2023 Business Results

Retrieved on:

Tuesday, March 26, 2024

2023 was a standout year for commercetools.

Key Points:

2023 was a standout year for commercetools.
Our robust business momentum and fiscal results are evidence of the value customers find in commercetools and composable commerce," said Dirk Hoerig, co-founder and CEO of commercetools.
Customer base is now equally split across EMEA and the Americas, solidifying commercetools' global expansion and underscoring the company's strong foothold in the American market as a European SaaS company.
In the last 18 months, the company announced six new products, including commercetools Connect , commercetools Checkout and commercetools Foundry , making it easier than ever to infuse composability into the modern commerce stack.

Nicox Appoints Experienced Biotech Executive Gavin Spencer as CEO

Retrieved on:

Wednesday, February 28, 2024

Pfizer, Chemistry, Bausch & Lomb, Novartis, Doctor of Philosophy, University, Therapy, Boots (company), NCX, Corporation, Glaucoma, Kowa, Partnership, Management

Gavin Spencer was most recently Executive Vice-President, Chief Business Officer & Head of Corporate Development at Nicox.

Key Points:

Gavin Spencer was most recently Executive Vice-President, Chief Business Officer & Head of Corporate Development at Nicox.
“I am delighted to welcome Gavin Spencer to his new role as CEO of Nicox.
Gavin brings exhaustive industry experience, particularly related to strategic partnership agreements and financing.
During his time with Nicox, since 2005, Gavin Spencer has had a key role in building and managing Nicox’s partnerships, including closing agreements with Pfizer, Bausch + Lomb, VISUfarma and Ocumension Therapeutics.

Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

Retrieved on:

Wednesday, February 28, 2024

General Health, Health, Optical, Annual general meeting, Bausch & Lomb, Management

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the “Board”), effective immediately.

Key Points:

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the “Board”), effective immediately.
Current director Richard De Schutter will retire from the Board effective as of the company’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”).
With Ms. Ling’s appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting.
“Since my return to the company, Richard has been a trusted advisor,” said Brent Saunders, chairman and CEO, Bausch + Lomb.

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance

Retrieved on:

Wednesday, February 21, 2024

Medical Supplies, Medical Devices, Health, Surgery, Pharmaceutical, Optical, Acquisition, Ophthalmology, Bausch, Care, Forecasting, News, Bausch & Lomb, Intraocular lens, Adjustment, GAAP, EPS, Ultra, Video game

For the fourth quarter of 2023, the change was primarily due to higher interest expense and the decrease in operating results noted above.

Key Points:

For the fourth quarter of 2023, the change was primarily due to higher interest expense and the decrease in operating results noted above.
Adjusted EPS attributable to Bausch + Lomb Corporation (non-GAAP)1 for the fourth quarter of 2023 was $0.24, as compared to $0.23 for the fourth quarter of 2022.
Adjusted EPS attributable to Bausch + Lomb Corporation (non-GAAP)1 for the full year of 2023 was $0.73, as compared to $1.07 for the full year of 2022.
Bausch + Lomb provided guidance for the full year of 2024, as follows.

Water Street Healthcare Partners Announces Appointment of Joseph Gordon

Retrieved on:

Tuesday, February 20, 2024

Marketing, Pfizer, Water, Growth, Bausch & Lomb, Investment, Pharmaceutical industry

CHICAGO, Feb. 20, 2024 /PRNewswire/ -- Water Street Healthcare Partners, an investment firm dedicated to building market leaders in health care, today announced that Joe Gordon has joined its team as an executive advisor. The health care leader, who most recently served as an executive with Bausch + Lomb, will work with Water Street on opportunities to invest in and grow medical products businesses.

Key Points:

CHICAGO, Feb. 20, 2024 /PRNewswire/ -- Water Street Healthcare Partners , an investment firm dedicated to building market leaders in health care, today announced that Joe Gordon has joined its team as an executive advisor.
The health care leader, who most recently served as an executive with Bausch + Lomb, will work with Water Street on opportunities to invest in and grow medical products businesses.
As I considered my next career step, Water Street stood out for its approach to building businesses that positively impact health care.
The health care firm currently manages more than $6 billion of capital dedicated to investing in and growing health care businesses.

Ace Vision Group Names Val Kolesnitchenko, MD as Chief Scientific Officer

Retrieved on:

Tuesday, February 13, 2024

Ophthalmology, Alcon, Research, FDA, Presbyopia, Ageing, Bausch & Lomb, Eye, Executive, Patient, Disease, Val, Science, Bausch, LSM, Medical device

BOSTON, Feb. 13, 2024 /PRNewswire/ -- Ace Vision Group, Inc., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye and presbyopia, announced that it has named Val Kolesnitchenko, MD, as Chief Scientific Officer.

Key Points:

BOSTON, Feb. 13, 2024 /PRNewswire/ -- Ace Vision Group, Inc., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye and presbyopia, announced that it has named Val Kolesnitchenko, MD , as Chief Scientific Officer.
"Dr. Kolesnitchenko has a strong foundation in both surgical and therapeutic ophthalmology, as well as highly developed interpersonal skills and industry relationships," said Dr. AnnMarie Hipsley, CEO of Ace Vision Group.
Val's assignment to the company as Chief Scientific Officer comes at a very timely period in the company's preparations for its medical device regulatory submissions.
"I look forward to working with Ace Vision Group on this revolutionary approach to presbyopia," said Dr. Kolesnitchenko.